Systemic capillary leak syndrome: a nosological entity that the nephrologist must be aware of.

J Nephrol

Associazione Nefrologica Gabriella Sebastio, Martina Franca, Italy.

Published: March 2025

Capillary leak syndrome occurs when plasma leaks out of capillaries into muscles, tissues, organs and body cavities. There are two major types of capillary leak syndrome: 1. secondary capillary leak syndrome: it is a single episode triggered by another disease, condition or drug; 2. idiopathic systemic capillary leak syndrome: it is a rare disease characterized by recurrent episodes of acute life-threatening episodes of shock, hemoconcentration, and hypoalbuminemia. An increase in capillary permeability results in reversible plasma movement into the interstitial spaces followed by the appearance of related symptoms or complications, including acute kidney injury. Cytokines are likely to be important in the pathophysiology of systemic capillary leak syndrome. Fluid management is a critical part of the treatment of systemic capillary leak syndrome: hypovolemia and hypotension can cause organ injury, whereas capillary leakage of administered fluid can worsen organ edema leading to progressive organ injury.Although systemic capillary leak syndrome is a rare entity, it can be life-threatening. The nephrologist must be aware of the potential and serious complications linked to this pathology, including the need for kidney replacement therapy. This review aims to increase awareness of systemic capillary leak syndrome in the nephrology community.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40620-025-02250-4DOI Listing

Publication Analysis

Top Keywords

capillary leak
36
leak syndrome
36
systemic capillary
24
capillary
10
leak
9
syndrome
9
nephrologist aware
8
syndrome rare
8
systemic
6
syndrome nosological
4

Similar Publications

Introduction: The pathognomonic feature of dengue shock syndrome (DSS) is a transient capillary leak syndrome resulting in profound intravascular volume depletion. WHO management guidelines recommend particular parenteral fluid regimens during the critical leakage phase, including synthetic colloid solutions in certain circumstances. We set out to describe the actual fluid management strategies employed in different settings and to investigate relationships with clinical outcomes.

View Article and Find Full Text PDF

Clarkson disease in critically and non-critically ill patients: insights from the Italian IRIS-CLS registry.

Intern Emerg Med

March 2025

Division of Internal Medicine, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, University of Milan, Via G.B. Grassi 74, 20157, Milan, Italy.

Idiopathic Systemic Capillary Leak Syndrome (ISCLS) is a poorly understood paroxysmal permeability disorder. This study aimed to characterize the clinical features and severity markers of ISCLS in critically and non-critically ill patients. We analyzed prospectively and retrospectively collected data on ISCLS cases from the Italian IRIS-CLS Registry (January 1995-December 2023).

View Article and Find Full Text PDF

Systemic capillary leak syndrome: a nosological entity that the nephrologist must be aware of.

J Nephrol

March 2025

Associazione Nefrologica Gabriella Sebastio, Martina Franca, Italy.

Capillary leak syndrome occurs when plasma leaks out of capillaries into muscles, tissues, organs and body cavities. There are two major types of capillary leak syndrome: 1. secondary capillary leak syndrome: it is a single episode triggered by another disease, condition or drug; 2.

View Article and Find Full Text PDF

SHR-1916: A Novel PEGylated Interleukin-2 Analogue with Altered Cellular Selectivity and Improved Pharmacokinetic Profiles for Cancer Immunotherapy.

Drug Des Devel Ther

March 2025

Jiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.

Purpose: Human interleukin-2 (IL-2) stimulates the differentiation and expansion of diverse immune cells dose-dependently. As an immunotherapy agent to treat metastatic cancers, IL-2 has been used in clinical practice and has demonstrated clear antitumor effects; however, its short half-life, the risk of capillary leak syndrome, and the unintended activation of immunosuppressive T cells hinder its clinical application. To address these challenges, a novel PEGylated interleukin-2 analogue, SHR-1916, was designed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!